Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$15.13 USD

15.13
7,419,063

-0.21 (-1.37%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $15.12 -0.01 (-0.07%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D

Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.

Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch

Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.

Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion

Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.

CVS Health (CVS) Nears Completion of $8B SGFY Acquisition

According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.

Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF

Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day.

Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients

Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.

Abbott's (ABT) CardioMEMS Favors Heart Failure Management

Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Smith & Nephew's (SNN) CIT Technology Favored by New Study

Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Henry Schein (HSIC) Bolsters Dental Practices With AI Tools

Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.

Zacks.com featured highlights include Catalyst Pharmaceuticals, Terex and Arista Networks

Catalyst Pharmaceuticals, Terex and Arista Networks are part of the Zacks Screen of the Week article.

Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know

Catalyst Pharmaceutical (CPRX) closed at $16.53 in the latest trading session, marking a +0.79% move from the prior day.

Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care

Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.

Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Tirthankar Chakraborty headshot

3 Stocks With Solid Earnings Growth to Buy Right Away

Invest in stocks like Catalyst Pharmaceuticals (CPRX), Terex (TEX) & Arista Networks (ANET) at the moment for superb earnings growth.

Is It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Catalyst (CPRX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Acadia (ACHC) in Your Portfolio

Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?

Adobe's (ADBE) first-quarter fiscal 2023 results are expected to reflect gains from solid momentum across the Digital Media and Digital Experience segments.